Syncom Formulations (India) Ltd logo

Syncom Formulations (India) Ltd

NSE: SYNCOMF BSE: 524470

₹20.29

+0.05 (0.25%)

Sun, 22 Nov 2026, 03:15 am

mtf coin illustrationMTF 5xInvest in Syncom Formulations (India) Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)1908.2
PE Ratio22.30
Dividend0.49
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Syncom Formulations (India) Analysis

dividend

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Unable to calculate sustainability of dividends as Syncom Formulations (India) has not reported any payouts.
    • Unable to evaluate Syncom Formulations (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
    • Unable to evaluate Syncom Formulations (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.

    health

    thumbs up icon

    Pros

    • Syncom Formulations (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
    • Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
    • Syncom Formulations (India) is profitable, therefore cash runway is not a concern.
    • Debt is well covered by operating cash flow (98.3%, greater than 20% of total debt).
    • Debt is covered by short term assets, assets are 9.3x debt.
    • Syncom Formulations (India)'s cash and other short term assets cover its long term commitments.
    • Syncom Formulations (India) earns more interest than it pays, coverage of interest payments is not a concern.
    • Syncom Formulations (India)'s level of debt (6.3%) compared to net worth is satisfactory (less than 40%).
    thumbs up icon

    Cons

    • The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
    • High level of physical assets or inventory.

    management

    thumbs up icon

    Pros

    • The average tenure for the Syncom Formulations (India) board of directors is over 10 years, this suggests they are a seasoned and experienced board.
    • Vijay's remuneration is lower than average for companies of similar size in India.
    • Vijay's compensation has been consistent with company performance over the past year, both up more than 20%.
    • More shares have been bought than sold by Syncom Formulations (India) individual insiders in the past 3 months.
    • The average tenure for the Syncom Formulations (India) management team is over 5 years, this suggests they are a seasoned and experienced team.
    thumbs up icon

    Cons

      misc

      thumbs up icon

      Pros

        thumbs up icon

        Cons

        • Syncom Formulations (India) is not covered by any analysts.
        • Syncom Formulations (India) has significant price volatility in the past 3 months.

        past

        thumbs up icon

        Pros

        • Syncom Formulations (India)'s 1-year earnings growth exceeds its 5-year average (22% vs 5.1%)
        • Syncom Formulations (India)'s year on year earnings growth rate has been positive over the past 5 years.
        thumbs up icon

        Cons

        • Syncom Formulations (India) used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
        • Syncom Formulations (India)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
        • Syncom Formulations (India) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
        • Syncom Formulations (India)'s earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (22% vs 22.7%).

        value

        thumbs up icon

        Pros

        • Syncom Formulations (India) is good value based on assets compared to the IN Pharmaceuticals industry average.
        • Syncom Formulations (India) is good value based on earnings compared to the IN Pharmaceuticals industry average.
        • Syncom Formulations (India) is good value based on earnings compared to the India market.
        • 524470 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
        • 524470 outperformed the Market in India which returned -14.5% over the past year.
        • BSE:524470 is up 54.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
        • BSE:524470 is up 54.9% outperforming the market in India which returned 8% over the past month.
        thumbs up icon

        Cons

        • Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
        • Syncom Formulations (India)'s share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
        pocketful logo lightpocketful logo dark
        PricingBecome a Partner
        search icon
        /

        No results for ''

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd

        Recent search

            Log In
            search icon

            No results for ‘’

              Popular search

              • popular search iconSuzlon Energy Ltd
              • popular search iconIndian Railway Finance Corporation Ltd
              • popular search iconTata Motors Ltd
              • popular search iconTata Steel Ltd
              • popular search iconRail Vikas Nigam Ltd
              • popular search iconReliance Industries Ltd
              pocketful logo lightpocketful logo dark
              • Pricing
              • Become a Partner
              Log In
              • home icon
              • arrow iconstocks
              • arrow iconsyncom formulations india ltd
              • arrow iconanalysis
              • Overview
              • Analysis
              • Financials
              • Ratios
              • shareholding
              • Technical Analysis
              • Corporate Actions
              • Peer Comparison
              • About
              • Company History
              • Deals
              • News
              • FAQs

              Open Your Free Demat Account Now!

              Step into a world of zero fees and limitless opportunities!

              pocketful logo
              • Quick Links

                • Open Demat Account
                • Pocketful Web
                • Pocketful App
                • Pricing
                • Authorised Person
                • Pocketful Calculators
                • Compliance Links
              • Pages

                • Tools
                • Blogs
                • ETF Screener
                • IPO
                • ETF
                • Bonds
                • Index Heat Map
              • Products

                • Stocks
                • Commodity
                • Subscription
                • Free Stock Screener
                • Pocketful GPT
                • MTF
                • Mutual Funds
              • Company

                • About us
                • Contact us
                • Terms and Conditions
                • Policies & Procedures
                • Privacy Policy
                • Disclosure
                • Careers
              • Socials

                • Facebook iconFacebook
                • Twitter iconTwitter
                • Instagram iconInstagram
                • LinkedIn iconLinkedIn
                • Youtube iconYoutube

              2022-25 Pocketful. All rights reserved, Built with in India

              Version -5.76

              app image 1app image 2

              Stocks:

              AllABCDEFGHIJKLMNOPQRSTUVWXYZ

              Explore

              Calculators
              Popular Calculators
              Group Stocks
              Asset Management Companies
              Popular Stocks
              Indian Indices
              Sector Wise Stocks
              IPO
              Share Market
              Best MF Schemes
              Platforms
              Resources
              Gold Rates in Top Cities
              Silver Rates in Top Cities

              Others:

              NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

              Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800